Calista Therapeutics

Calista Therapeutics is developing proprietary peptide drugs for Cystic Fibrosis that are 12 months from IND enablement and clinical trials.

Elevator Pitch

Cystic Fibrosis (CF) is an inherited lung disease with 30,000 US patients with a life expectancy of 37. There is no treatment for 96% of patients and a high unmet clinical need. Novel inhaled lead drug, Procaftor, shows clinically predictive efficacy in a human CF model. CF is an orphan disease with a lean development model. Our experienced CF drug development team are asking for a $8m to fund a 3 year IND to end of Phase 2a with several investor exits. We anticipate peak US sales of $1.2bn.

Newsletter signup
MassChallenge Logo

© 2016 MassChallenge